Case Report
Successful Use of Tocilizumab in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis
Table 1
Summary of medical treatment offered to patient.
| | Duration | Reason for discontinuation |
| Drug for RA | | | Methotrexate (5 mg per week) | Max 15 months | Nausea | Methotrexate (7.5 mg to 10 mg per week) | Max 10 months | Nausea, malaise | Sulfasalazine | Less than 3 months | Mouth ulcers | Hydroxychloroquine | 6 months | Taste disturbance | Leflunomide | 30 months | Mouth and oesophageal ulcers | Azathioprine | 3 months | Nausea, headache | Etanercept (monotherapy) | 2 months | Facial flush, panic attacks | Infliximab (in combination with Methotrexate) | 11 months | Facial flush, headache, depression | Drug for UC | | | Asacol MR | 4 months | Oral and pharyngeal mucositis | Treatments declined by patient | | Ciclosporin | Worried about side effects | Other oral mesalazine preparations | Rituximab |
|
|
Methotrexate was rechallenged alone or in combination on multiple occasions.
|